Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 98 entries
Sorted by: Best Match Show Resources per page
Mexiletine Can Be Used to Prevent and Reduce Facial Wrinkles.

The Journal of craniofacial surgery

Sun P, Lu M, Luan F, Pan B.
PMID: 34608011
J Craniofac Surg. 2021 Oct 04; doi: 10.1097/SCS.0000000000008262. Epub 2021 Oct 04.

No abstract available.

Cite
Sun P, Lu M, Luan F, et al. Mexiletine Can Be Used to Prevent and Reduce Facial Wrinkles. J Craniofac Surg. 2021;doi: 10.1097/SCS.0000000000008262.
Sun, P., Lu, M., Luan, F., & Pan, B. (2021). Mexiletine Can Be Used to Prevent and Reduce Facial Wrinkles. The Journal of craniofacial surgery, . https://doi.org/10.1097/SCS.0000000000008262
Sun, Pengfei, et al. "Mexiletine Can Be Used to Prevent and Reduce Facial Wrinkles." The Journal of craniofacial surgery vol. (2021). doi: https://doi.org/10.1097/SCS.0000000000008262
Sun P, Lu M, Luan F, Pan B. Mexiletine Can Be Used to Prevent and Reduce Facial Wrinkles. J Craniofac Surg. 2021 Oct 04; doi: 10.1097/SCS.0000000000008262. Epub 2021 Oct 04. PMID: 34608011.
Copy Download .nbib Format: NLM
Illustrative and historic cases of phenoconversion.

American journal of translational research

Michaud V, Dow P, Turgeon J.
PMID: 35035679
Am J Transl Res. 2021 Dec 15;13(12):13328-13335. eCollection 2021.

Intersubject variability in drug response, whether related to efficacy or toxicity, is well recognized clinically. Over the years, drug selection from our pharmacologic armamentarium has moved from providers' preferred choices to more personalized treatments as clinicians' decisions are guided...

Cite
Michaud V, Dow P, Turgeon J. Illustrative and historic cases of phenoconversion. Am J Transl Res. 2021;13(12):13328-13335
Michaud, V., Dow, P., & Turgeon, J. (2021). Illustrative and historic cases of phenoconversion. American journal of translational research, 13(12), 13328-13335.
Michaud, Veronique, et al. "Illustrative and historic cases of phenoconversion." American journal of translational research vol. 13,12 (2021): 13328-13335.
Michaud V, Dow P, Turgeon J. Illustrative and historic cases of phenoconversion. Am J Transl Res. 2021 Dec 15;13(12):13328-13335. eCollection 2021. PMID: 35035679; PMCID: PMC8748136.
Copy Download .nbib Format: NLM
Anti-Bronchospasmodic Effect of JME-173, a Novel Mexiletine Analog Endowed With Highly Attenuated Anesthetic Activity.

Frontiers in pharmacology

Carvalho KIM, Coutinho DS, Joca HC, Miranda AS, Cruz JDS, Silva ET, Souza MVN, Faria RX, Silva PMRE, Costa JCS, Martins MA.
PMID: 32903732
Front Pharmacol. 2020 Jul 30;11:1159. doi: 10.3389/fphar.2020.01159. eCollection 2020.

Local anesthetics (LAs), such as lidocaine and mexiletine, inhibit bronchoconstriction in asthmatics, but adverse effects limit their use for this specific clinical application. In this study, we describe the anti-spasmodic properties of the mexiletine analog 2-(2-aminopropoxy)-3,5-dimethyl, 4-Br-benzene (JME-173), which...

Cite
Carvalho KIM, Coutinho DS, Joca HC, et al. Anti-Bronchospasmodic Effect of JME-173, a Novel Mexiletine Analog Endowed With Highly Attenuated Anesthetic Activity. Front Pharmacol. 2020;11:1159doi: 10.3389/fphar.2020.01159.
Carvalho, K. I. M., Coutinho, D. S., Joca, H. C., Miranda, A. S., Cruz, J. D. S., Silva, E. T., Souza, M. V. N., Faria, R. X., Silva, P. M. R. E., Costa, J. C. S., & Martins, M. A. (2020). Anti-Bronchospasmodic Effect of JME-173, a Novel Mexiletine Analog Endowed With Highly Attenuated Anesthetic Activity. Frontiers in pharmacology, 111159. https://doi.org/10.3389/fphar.2020.01159
Carvalho, Katharinne Ingrid Moraes, et al. "Anti-Bronchospasmodic Effect of JME-173, a Novel Mexiletine Analog Endowed With Highly Attenuated Anesthetic Activity." Frontiers in pharmacology vol. 11 (2020): 1159. doi: https://doi.org/10.3389/fphar.2020.01159
Carvalho KIM, Coutinho DS, Joca HC, Miranda AS, Cruz JDS, Silva ET, Souza MVN, Faria RX, Silva PMRE, Costa JCS, Martins MA. Anti-Bronchospasmodic Effect of JME-173, a Novel Mexiletine Analog Endowed With Highly Attenuated Anesthetic Activity. Front Pharmacol. 2020 Jul 30;11:1159. doi: 10.3389/fphar.2020.01159. eCollection 2020. PMID: 32903732; PMCID: PMC7438868.
Copy Download .nbib Format: NLM
Efficacy and tolerability of quinidine as salvage therapy for monomorphic ventricular tachycardia in patients with structural heart disease.

Journal of cardiovascular electrophysiology

Deshmukh A, Larson J, Ghannam M, Saeed M, Cunnane R, Ghanbari H, Latchamsetty R, Crawford T, Jongnarangsin K, Pelosi F, Chugh A, Oral H, Morady F, Bogun F, Liang JJ.
PMID: 34586686
J Cardiovasc Electrophysiol. 2021 Dec;32(12):3173-3178. doi: 10.1111/jce.15260. Epub 2021 Oct 06.

INTRODUCTION: Quinidine is an effective therapy for a subset of polymorphic ventricular tachycardia and ventricular fibrillation (VF) syndromes; however, the efficacy of quinidine in scar-related monomorphic ventricular tachycardia (MMVT) is unclear.METHODS AND RESULTS: Between 2009 and 2020 a single...

Cite
Deshmukh A, Larson J, Ghannam M, et al. Efficacy and tolerability of quinidine as salvage therapy for monomorphic ventricular tachycardia in patients with structural heart disease. J Cardiovasc Electrophysiol. 2021;32(12):3173-3178doi: 10.1111/jce.15260.
Deshmukh, A., Larson, J., Ghannam, M., Saeed, M., Cunnane, R., Ghanbari, H., Latchamsetty, R., Crawford, T., Jongnarangsin, K., Pelosi, F., Chugh, A., Oral, H., Morady, F., Bogun, F., & Liang, J. J. (2021). Efficacy and tolerability of quinidine as salvage therapy for monomorphic ventricular tachycardia in patients with structural heart disease. Journal of cardiovascular electrophysiology, 32(12), 3173-3178. https://doi.org/10.1111/jce.15260
Deshmukh, Amrish, et al. "Efficacy and tolerability of quinidine as salvage therapy for monomorphic ventricular tachycardia in patients with structural heart disease." Journal of cardiovascular electrophysiology vol. 32,12 (2021): 3173-3178. doi: https://doi.org/10.1111/jce.15260
Deshmukh A, Larson J, Ghannam M, Saeed M, Cunnane R, Ghanbari H, Latchamsetty R, Crawford T, Jongnarangsin K, Pelosi F, Chugh A, Oral H, Morady F, Bogun F, Liang JJ. Efficacy and tolerability of quinidine as salvage therapy for monomorphic ventricular tachycardia in patients with structural heart disease. J Cardiovasc Electrophysiol. 2021 Dec;32(12):3173-3178. doi: 10.1111/jce.15260. Epub 2021 Oct 06. PMID: 34586686.
Copy Download .nbib Format: NLM
Synthesis of Mexiletine Stereoisomers and Related Compounds via S(N)Ar Nucleophilic Substitution of a Cr(CO)(3)-Complexed Aromatic Fluoride.

The Journal of organic chemistry

Loughhead DG, Flippin LA, Weikert RJ.
PMID: 11674449
J Org Chem. 1999 Apr 30;64(9):3373-3375. doi: 10.1021/jo982287c.

No abstract available.

Cite
Loughhead DG, Flippin LA, Weikert RJ. Synthesis of Mexiletine Stereoisomers and Related Compounds via S(N)Ar Nucleophilic Substitution of a Cr(CO)(3)-Complexed Aromatic Fluoride. J Org Chem. 1999;64(9):3373-3375doi: 10.1021/jo982287c.
Loughhead, D. G., Flippin, L. A., & Weikert, R. J. (1999). Synthesis of Mexiletine Stereoisomers and Related Compounds via S(N)Ar Nucleophilic Substitution of a Cr(CO)(3)-Complexed Aromatic Fluoride. The Journal of organic chemistry, 64(9), 3373-3375. https://doi.org/10.1021/jo982287c
Loughhead, David G., et al. "Synthesis of Mexiletine Stereoisomers and Related Compounds via S(N)Ar Nucleophilic Substitution of a Cr(CO)(3)-Complexed Aromatic Fluoride." The Journal of organic chemistry vol. 64,9 (1999): 3373-3375. doi: https://doi.org/10.1021/jo982287c
Loughhead DG, Flippin LA, Weikert RJ. Synthesis of Mexiletine Stereoisomers and Related Compounds via S(N)Ar Nucleophilic Substitution of a Cr(CO)(3)-Complexed Aromatic Fluoride. J Org Chem. 1999 Apr 30;64(9):3373-3375. doi: 10.1021/jo982287c. PMID: 11674449.
Copy Download .nbib Format: NLM
Mexiletine shortens the QT interval in a pedigree of .

Journal of arrhythmia

Fujisawa T, Aizawa Y, Katsumata Y, Kimura K, Hashimoto K, Yamashita T, Miyama H, Kimura T, Kosaki K, Takatsuki S, Shimizu W, Fukuda K.
PMID: 32071644
J Arrhythm. 2020 Jan 08;36(1):193-196. doi: 10.1002/joa3.12300. eCollection 2020 Feb.

A 23-year-old female had been suffering from recurrent syncopal episodes during sleep since her childhood. She had a family history of sudden death and her QTc interval was remarkably prolonged to 537 ms A Holter ECG revealed torsade de...

Cite
Fujisawa T, Aizawa Y, Katsumata Y, et al. Mexiletine shortens the QT interval in a pedigree of . J Arrhythm. 2020;36(1):193-196doi: 10.1002/joa3.12300.
Fujisawa, T., Aizawa, Y., Katsumata, Y., Kimura, K., Hashimoto, K., Yamashita, T., Miyama, H., Kimura, T., Kosaki, K., Takatsuki, S., Shimizu, W., & Fukuda, K. (2020). Mexiletine shortens the QT interval in a pedigree of . Journal of arrhythmia, 36(1), 193-196. https://doi.org/10.1002/joa3.12300
Fujisawa, Taishi, et al. "Mexiletine shortens the QT interval in a pedigree of ." Journal of arrhythmia vol. 36,1 (2020): 193-196. doi: https://doi.org/10.1002/joa3.12300
Fujisawa T, Aizawa Y, Katsumata Y, Kimura K, Hashimoto K, Yamashita T, Miyama H, Kimura T, Kosaki K, Takatsuki S, Shimizu W, Fukuda K. Mexiletine shortens the QT interval in a pedigree of . J Arrhythm. 2020 Jan 08;36(1):193-196. doi: 10.1002/joa3.12300. eCollection 2020 Feb. PMID: 32071644; PMCID: PMC7011830.
Copy Download .nbib Format: NLM
AhR Activation in Pharmaceutical Development: Applying Liver Gene Expression Biomarker Thresholds to Identify Doses Associated with Tumorigenic Risks in Rats.

Toxicological sciences : an official journal of the Society of Toxicology

Qin C, Aslamkhan AG, Pearson K, Tanis KQ, Podtelezhnikov A, Frank E, Pacchione S, Pippert T, Glaab WE, Sistare FD.
PMID: 31127949
Toxicol Sci. 2019 May 25; doi: 10.1093/toxsci/kfz125. Epub 2019 May 25.

Aryl hydrocarbon receptor (AhR) activation is associated with carcinogenicity of non-genotoxic AhR-activating carcinogens such as 2, 3, 7, 8-tetrachlorodibenzodioxin (TCDD), and is often observed with drug candidate molecules in development and raises safety concerns. As downstream effectors of AhR...

Cite
Qin C, Aslamkhan AG, Pearson K, et al. AhR Activation in Pharmaceutical Development: Applying Liver Gene Expression Biomarker Thresholds to Identify Doses Associated with Tumorigenic Risks in Rats. Toxicol Sci. 2019;doi: 10.1093/toxsci/kfz125.
Qin, C., Aslamkhan, A. G., Pearson, K., Tanis, K. Q., Podtelezhnikov, A., Frank, E., Pacchione, S., Pippert, T., Glaab, W. E., & Sistare, F. D. (2019). AhR Activation in Pharmaceutical Development: Applying Liver Gene Expression Biomarker Thresholds to Identify Doses Associated with Tumorigenic Risks in Rats. Toxicological sciences : an official journal of the Society of Toxicology, . https://doi.org/10.1093/toxsci/kfz125
Qin, Chunhua, et al. "AhR Activation in Pharmaceutical Development: Applying Liver Gene Expression Biomarker Thresholds to Identify Doses Associated with Tumorigenic Risks in Rats." Toxicological sciences : an official journal of the Society of Toxicology vol. (2019). doi: https://doi.org/10.1093/toxsci/kfz125
Qin C, Aslamkhan AG, Pearson K, Tanis KQ, Podtelezhnikov A, Frank E, Pacchione S, Pippert T, Glaab WE, Sistare FD. AhR Activation in Pharmaceutical Development: Applying Liver Gene Expression Biomarker Thresholds to Identify Doses Associated with Tumorigenic Risks in Rats. Toxicol Sci. 2019 May 25; doi: 10.1093/toxsci/kfz125. Epub 2019 May 25. PMID: 31127949.
Copy Download .nbib Format: NLM
Inhibitory effects of class I antiarrhythmic agents on Na.

Regenerative therapy

Yonemizu S, Masuda K, Kurata Y, Notsu T, Higashi Y, Fukumura K, Li P, Ninomiya H, Miake J, Tsuneto M, Shirayoshi Y, Hisatome I.
PMID: 30766898
Regen Ther. 2019 Feb 01;10:104-111. doi: 10.1016/j.reth.2018.12.002. eCollection 2019 Jun.

INTRODUCTION: Human induced pluripotent stem cells (hiPSCs) harboring cardiac myosin heavy chain 6 promoter can differentiate into functional cardiomyocytes called "iCell cardiomyocytes" under blasticidin treatment condition. While iCell cardiomyocytes are expected to be used for predicting cardiotoxicity of drugs,...

Cite
Yonemizu S, Masuda K, Kurata Y, et al. Inhibitory effects of class I antiarrhythmic agents on Na. Regen Ther. 2019;10:104-111doi: 10.1016/j.reth.2018.12.002.
Yonemizu, S., Masuda, K., Kurata, Y., Notsu, T., Higashi, Y., Fukumura, K., Li, P., Ninomiya, H., Miake, J., Tsuneto, M., Shirayoshi, Y., & Hisatome, I. (2019). Inhibitory effects of class I antiarrhythmic agents on Na. Regenerative therapy, 10104-111. https://doi.org/10.1016/j.reth.2018.12.002
Yonemizu, Sayaka, et al. "Inhibitory effects of class I antiarrhythmic agents on Na." Regenerative therapy vol. 10 (2019): 104-111. doi: https://doi.org/10.1016/j.reth.2018.12.002
Yonemizu S, Masuda K, Kurata Y, Notsu T, Higashi Y, Fukumura K, Li P, Ninomiya H, Miake J, Tsuneto M, Shirayoshi Y, Hisatome I. Inhibitory effects of class I antiarrhythmic agents on Na. Regen Ther. 2019 Feb 01;10:104-111. doi: 10.1016/j.reth.2018.12.002. eCollection 2019 Jun. PMID: 30766898; PMCID: PMC6360514.
Copy Download .nbib Format: NLM
Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress.

Frontiers in cellular neuroscience

Rojas F, Cortes N, Abarzua S, Dyrda A, van Zundert B.
PMID: 24570655
Front Cell Neurosci. 2014 Feb 07;8:24. doi: 10.3389/fncel.2014.00024. eCollection 2014.

Amyotrophic lateral sclerosis (ALS) is a fatal paralytic disorder caused by dysfunction and degeneration of motor neurons. Multiple disease-causing mutations, including in the genes for SOD1 and TDP-43, have been identified in ALS. Astrocytes expressing mutant SOD1 are strongly...

Cite
Rojas F, Cortes N, Abarzua S, et al. Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front Cell Neurosci. 2014;8:24doi: 10.3389/fncel.2014.00024.
Rojas, F., Cortes, N., Abarzua, S., Dyrda, A., & van Zundert, B. (2014). Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Frontiers in cellular neuroscience, 824. https://doi.org/10.3389/fncel.2014.00024
Rojas, Fabiola, et al. "Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress." Frontiers in cellular neuroscience vol. 8 (2014): 24. doi: https://doi.org/10.3389/fncel.2014.00024
Rojas F, Cortes N, Abarzua S, Dyrda A, van Zundert B. Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front Cell Neurosci. 2014 Feb 07;8:24. doi: 10.3389/fncel.2014.00024. eCollection 2014. PMID: 24570655; PMCID: PMC3916762.
Copy Download .nbib Format: NLM
The influence of urinary pH on the elimination of mexiletine.

British journal of clinical pharmacology

Kiddie MA, Kaye CM, Turner P, Shaw TR.
PMID: 22454952
Br J Clin Pharmacol. 1974 Jun;1(3):229-32. doi: 10.1111/j.1365-2125.1974.tb00241.x.

1 The plasma elimination half-life of mexiletine was measured in four subjects when the urine was rendered (a) acidic and (b) alkaline. 2 Urinary acidification (pH 5.0) was associated with a plasma elimination half-life of 2.8 h and 57.5%...

Cite
Kiddie MA, Kaye CM, Turner P, et al. The influence of urinary pH on the elimination of mexiletine. Br J Clin Pharmacol. 1974;1(3):229-32doi: 10.1111/j.1365-2125.1974.tb00241.x.
Kiddie, M. A., Kaye, C. M., Turner, P., & Shaw, T. R. (1974). The influence of urinary pH on the elimination of mexiletine. British journal of clinical pharmacology, 1(3), 229-32. https://doi.org/10.1111/j.1365-2125.1974.tb00241.x
Kiddie, M A, et al. "The influence of urinary pH on the elimination of mexiletine." British journal of clinical pharmacology vol. 1,3 (1974): 229-32. doi: https://doi.org/10.1111/j.1365-2125.1974.tb00241.x
Kiddie MA, Kaye CM, Turner P, Shaw TR. The influence of urinary pH on the elimination of mexiletine. Br J Clin Pharmacol. 1974 Jun;1(3):229-32. doi: 10.1111/j.1365-2125.1974.tb00241.x. PMID: 22454952; PMCID: PMC1402565.
Copy Download .nbib Format: NLM
Survival of a Newborn with 2:1 Atrioventricular Block, Long QT Syndrome, and Torsades de Pointes.

The Ochsner journal

Sarkar S, Brumund M, Darling R, Snyder CS.
PMID: 21603542
Ochsner J. 2007;7(4):181-4.

Long QT syndrome is a rare disorder that can manifest as syncope, Torsades de Pointes, or sudden cardiac death. We report a newborn with asymptomatic bradycardia, 2:1 atrioventricular block, long QT syndrome, and episodes of Torsades de Pointes. The...

Cite
Sarkar S, Brumund M, Darling R, et al. Survival of a Newborn with 2:1 Atrioventricular Block, Long QT Syndrome, and Torsades de Pointes. Ochsner J. 2007;7(4):181-4
Sarkar, S., Brumund, M., Darling, R., & Snyder, C. S. (2007). Survival of a Newborn with 2:1 Atrioventricular Block, Long QT Syndrome, and Torsades de Pointes. The Ochsner journal, 7(4), 181-4.
Sarkar, Shubho, et al. "Survival of a Newborn with 2:1 Atrioventricular Block, Long QT Syndrome, and Torsades de Pointes." The Ochsner journal vol. 7,4 (2007): 181-4.
Sarkar S, Brumund M, Darling R, Snyder CS. Survival of a Newborn with 2:1 Atrioventricular Block, Long QT Syndrome, and Torsades de Pointes. Ochsner J. 2007;7(4):181-4. PMID: 21603542; PMCID: PMC3096416.
Copy Download .nbib Format: NLM
Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres.

Frontiers in pharmacology

Carbonara R, Carocci A, Roussel J, Crescenzo G, Buonavoglia C, Franchini C, Lentini G, Camerino DC, Desaphy JF.
PMID: 26257653
Front Pharmacol. 2015 Jul 24;6:155. doi: 10.3389/fphar.2015.00155. eCollection 2015.

Voltage-gated sodium channels are known to play a pivotal role in perception and transmission of pain sensations. Gain-of-function mutations in the genes encoding the peripheral neuronal sodium channels, hNav1.7-1.9, cause human painful diseases. Thus while treatment of chronic pain...

Cite
Carbonara R, Carocci A, Roussel J, et al. Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres. Front Pharmacol. 2015;6:155doi: 10.3389/fphar.2015.00155.
Carbonara, R., Carocci, A., Roussel, J., Crescenzo, G., Buonavoglia, C., Franchini, C., Lentini, G., Camerino, D. C., & Desaphy, J. F. (2015). Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres. Frontiers in pharmacology, 6155. https://doi.org/10.3389/fphar.2015.00155
Carbonara, Roberta, et al. "Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres." Frontiers in pharmacology vol. 6 (2015): 155. doi: https://doi.org/10.3389/fphar.2015.00155
Carbonara R, Carocci A, Roussel J, Crescenzo G, Buonavoglia C, Franchini C, Lentini G, Camerino DC, Desaphy JF. Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres. Front Pharmacol. 2015 Jul 24;6:155. doi: 10.3389/fphar.2015.00155. eCollection 2015. PMID: 26257653; PMCID: PMC4513211.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 98 entries